TNFSF10 and pancreatic neoplasm: The present work demonstrate that CaM antagonists enhance TRAIL-induced apoptosis in resistant pancreatic cancer cells via novel mechanisms, which supports the use of these readily available drugs as promising interventions to improve the efficacy of TRAIL therapy.